This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	TTK protein kinase (TTK; MPS1)	<i>In vitro</i> and cell culture studies identified an orally bioavailable small molecule inhibitor of MPS1 that could help treat cancer. <i>In vitro</i> SAR studies based on a 1 <i>H</i> -pyrrolo[3,2- <i>c</i>]pyridine scaffold yielded a selective MPS1 inhibitor with an <i>in vitro</i> IC ₅₀ value of 0.04 μM that was stable in mouse and human microsomes. In a mouse xenograft model of human colon carcinoma, the inhibitor decreased MPS1 activity compared with no treatment. Next steps include testing drug candidates in mouse xenograft models of human breast cancer dependent on high MPS1 activity. SciBX 7(2); doi:10.1038/scibx.2014.50 Published online Jan. 16, 2014	Patented; licensed by the Cancer Research Technology Pioneer Fund	Naud, S. <i>et al.</i> <i>J. Med. Chem.</i> ; published online Nov. 20, 2013; doi:10.1021/jm401395s Contact: Julian Blagg, The Institute of Cancer Research, London, U.K. e-mail: julian.blagg@icr.ac.uk Contact: Rob L.M. van Montfort, same affiliation as above e-mail: rob.vanmontfort@icr.ac.uk